Examining the Role of the Orexin System in Sleep and Stress in Persons With Opioid Use Disorder
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Andrew S Huhn, PhD
- Phone Number: 410-550-1971
- Email: ahuhn1@jhu.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Behavioral Pharmacology Research Unit at the Johns Hopkins Bayview Medical Center
-
Baltimore, Maryland, United States, 21218
- Man Alive Inc., Lane Treatment Center
-
Baltimore, Maryland, United States, 21224
- Addiction Treatment Services at Johns Hopkins Bayview Medical Center
-
Bel Air, Maryland, United States, 21014
- Ashley Addiction Treatment
-
Elkton, Maryland, United States, 21921
- Ashley Addiction Treatment
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Between the ages of 21-65, inclusive.
- Past 30-day sleep disturbance as evidenced by a Pittsburgh Sleep Quality Index Total Score >5.
- Enrolled in either outpatient methadone-maintenance, buprenorphine-maintenance, or XR-NTX treatment for OUD.
- Willingness to be maintained on a protocolized dose starting between 60-130mg methadone or 380mg XR-NTX for the duration of the study.
- At least two weeks of continuous abstinence from illicit opioids as evidenced by self-report and urine drug screens collected as part of routine care.
- Willing to comply with the study protocol, which will include weekly study visits, daily actigraphy and ecological momentary assessments.
- Use of birth control throughout study.
- Have no clinically significant chronic medical disorders or conditions that are judged by the investigators to prevent participation.
Exclusion Criteria:
- Serious mental illnesses that are unstable and could affect study participation (thought disorders, hallucinations, delusions, thoughts of harm to self/others).
- Current moderate to severe substance use disorder other than OUD.
- Current illicit stimulant use, including cocaine and methamphetamine.
- Pregnant or breast feeding.
- Have a known allergy to the study medications.
- Past 30-day prescribed use of suvorexant.
- Current use of a benzodiazepine or other schedule IV medication for insomnia.
- Use of Cytochrome P450 3A inhibitors.
- Current narcolepsy, sleep paralysis, or restless leg syndrome as assessed by medical history
- Apnea-hypopnea index > 30.
- Use of glucocorticoid medications and any medication that would alter the hypothalamic-pituitary-adrenal axis.
- Past 30-day suicidal behavior as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS).
- Have circumstances that would interfere with study participation (e.g., impending jail; severe clinical issues).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Placebo sleep medication (2 placebo oral capsules)
|
Weight and color matched placebo
|
|
Active Comparator: Suvorexant
Sleep medication (20mg suvorexant; 2 10mg capsules; patients can self-titrate to 1 10mg capsule)
|
Dual orexin receptor antagonist
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total Sleep Time
Time Frame: 21 nights
|
Mean total number of minutes slept per night as measured by actigraphy and self-reported sleep diary.
Mean total sleep time will be collected over a seven-night period in weeks 1, 4, and 8 of the trial.
|
21 nights
|
|
Total Wake Time After Sleep Onset
Time Frame: 21 nights
|
Mean total number of minutes awake between initial sleep onset and final morning awakening, measured by actigraphy and self-reported sleep diary.
Mean wake after sleep onset will be collected over a seven-night period in weeks 1, 4, and 8 of the trial.
|
21 nights
|
|
Change in Perceived Stress Scale 4 (PSS-4) score
Time Frame: 21 days (collected over a seven-day period in weeks 1, 4, and 8 of the trial)
|
Mean daily scores on the PSS-4 (a four item scale self-reported scale than measures stress using a 0-4 Likert scale; total range of PSS-4 scores is 0-16; lower scores indicate lower daily stress relative to higher scores, which indicate higher daily stress).
Mean PSS-4 scores will be collected over a seven-day period in weeks 1, 4, and 8 of the trial.
|
21 days (collected over a seven-day period in weeks 1, 4, and 8 of the trial)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Andrew S Huhn, PhD, Johns Hopkins University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Narcotic-Related Disorders
- Nervous System Diseases
- Mental Disorders
- Substance-Related Disorders
- Chemically-Induced Disorders
- Sleep Wake Disorders
- Opioid-Related Disorders
- Parasomnias
- Sleep Aids, Pharmaceutical
- Orexin Receptor Antagonists
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Neurotransmitter Agents
- Hypnotics and Sedatives
- suvorexant
Other Study ID Numbers
Other Study ID Numbers
- IRB00223942
- U01HL150835 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.